The screening identified approved drugs previously reported to indirectly influence tau pathology or Alzheimer’s disease pathways, alongside natural products including Bryostatin-14, which is known to modulate kinases involved in tau phosphorylation. This evidence concerns the gene MAPT and early-onset autosomal dominant Alzheimer disease.